Get the Stockscreener App
10.44
2.55%
0.26
After Hours:
10.67
0.23
+2.20%
Omeros Corporation stock is traded at $10.44, with a volume of 631.67K.
It is up +2.55% in the last 24 hours and down -8.26% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$10.18
Open:
$10.36
24h Volume:
631.67K
Relative Volume:
0.30
Market Cap:
$740.20M
Revenue:
-
Net Income/Loss:
$-121.24M
P/E Ratio:
-5.1742
EPS:
-2.0177
Net Cash Flow:
$-105.32M
1W Performance:
-4.66%
1M Performance:
-8.26%
6M Performance:
+138.36%
1Y Performance:
+13.97%
1-Day Range:
$10.29
$10.73
1-Week Range:
$10.04
$11.44
52-Week Range:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
10.44 | 721.77M | 0 | -121.24M | -105.32M | -2.0177 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros (OMER) Projected to Post Earnings on Monday - MarketBeat
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - PharmiWeb.com
GeekWire Awards: Billion-dollar deals, rare IPO, pharma pact, and mega-round vie for Deal of the Year - GeekWire
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OMER SEC FilingsOmeros 10-K, 10-Q, 8-K Forms - Stock Titan
Is Omeros Corporation gaining market share2026 Valuation Update & Weekly High Potential Stock Alerts - baoquankhu1.vn
OMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros rises after pricing ~$22M stock offering - MSN
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - Stocktwits
Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug - Stocktwits
Omeros: Yartemlea Can Own The Label And Still Split The Market (NASDAQ:OMER) - Seeking Alpha
Omeros (OMER) Expected to Announce Earnings on Tuesday - MarketBeat
Omeros (NASDAQ: OMER) CEO exercises 400,000 options with tax share withholding - Stock Titan
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - PharmiWeb.com
Omeros Corporation Announces Successful Primate Study in OncotoX-AML Drug Program - marketscreener.com
Omeros (OMER) Shows Promising Results in Early Cancer Treatment Study - GuruFocus
Why Omeros Corporation stock could be next big winnerJuly 2025 Setups & Smart Swing Trading Alerts - mfd.ru
Is Omeros Corporation stock positioned well for digital economyJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - mfd.ru
What risks investors should watch in Omeros Corporation stockWeekly Investment Report & Long-Term Safe Investment Plans - mfd.ru
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Omeros Achieves Commercial Milestone with First Approved Drug Launch - AD HOC NEWS
Macro Review: What is the long term forecast for Omeros Corporation stockStock Surge & Community Shared Stock Ideas - baoquankhu1.vn
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance
Omeros wins FDA nod for transplant therapy - MSN
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest - MarketBeat
EV Market: Is Omeros Corporation gaining market shareTrade Entry Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
Vanguard discloses 4.0M-share Omeros Corp (NASDAQ: OMER) position - Stock Titan
Omeros higher after first commercial sales of transplant therapy - MSN
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros Shares Rise After Starting Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com Canada
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):